News Release 

Trial compares SSRI vs. placebo for obsessive-compulsive behaviors in kids, teens with ASD


Bottom Line: Researchers compared the selective serotonin reuptake inhibitor (SSRI) fluoxetine with placebo for reducing the frequency and severity of obsessive-compulsive behaviors in children and adolescents with autism spectrum disorder (ASD) in this randomized clinical trial in Australia. The trial included 146 participants (ages 7 to 18) with ASDs; 75 received fluoxetine and 71 received placebo for 16 weeks. Of the participants, 109 completed the trial. The authors report that for the primary outcome (total scores on an obsessive-compulsive scale modified for pervasive developmental disorder) treatment with fluoxetine compared with placebo resulted in lower scores for obsessive-compulsive behaviors but the interpretation of that finding is limited by a number of factors. These factors include the study's high dropout rate and significant differences found between groups in some measures at baseline.

To access the embargoed study: Visit our For The Media website at this link

Authors: Dinah S. Reddihough, M.D., of the Royal Children's Hospital, Melbourne, Australia, and coauthors.


Editor's Note: The article includes conflict of interest and funding/support disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

#  #  #

Media advisory: To contact corresponding author Dinah S. Reddihough, M.D., email The full study and editorial are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.